Matteo Megna1, Luisa Di Costanzo2, Giuseppe Argenziano3, Anna Balato4, Paola Colasanti5, Francesco Cusano2, Antonia G Galluccio6, Alessio Gambardella3, Serena Lembo7, Raffaele Mozzillo5, Genoveffa Scotto Di Luzio8, Gabriella Fabbrocini1, Nicola Balato1. 1. a Department of Dermatology , University of Naples Federico II , Naples , Italy. 2. b Dermatology Unit , G. Rummo Hospital , Benevento , Italy. 3. c Dermatology Unit , University of Campania Luigi Vanvitelli , Naples , Italy. 4. d Department of Advanced Biomedical Sciences , University of Naples Federico II , Naples , Italy. 5. e Dermatology Unit , "Ospedale del Mare" , Naples , Italy. 6. f Dermatology and Venereology Unit , Sacro Cuore di Gesù Fatebenefratelli Hospital , Benevento , Italy. 7. g Department of Medicine, Surgery and Dentistry , "Scuola Medica Salernitana" University of Salerno , Salerno , Italy. 8. h Sant'Anna and San Sebastiano Hospital , Caserta , Italy.
Abstract
Background: Long term data on the real-life use of secukinumab are scant. The aim of this study was to investigate the real-life effectiveness, safety and treatment persistence of secukinumab in patients with moderate-to-severe psoriasis. Research design and methods: This 84-week, multicenter (n = 7) retrospective study analyzed data from patients who initiated and received at least 6 months of secukinumab treatment between June 2016 and June 2018 in the Campania region of Italy. Patient demographic and treatment characteristics, duration of treatment and reasons for discontinuation as well as Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI) scores were assessed. Results: 324 patients (63% male, mean age 50.2 years) were enrolled and received a mean 11.7 months of secukinumab treatment. Overall, 9.5% discontinued secukinumab, including 5.2% who discontinued due to secondary inefficacy and 1.8% due to adverse events. PASI, BSA and DLQI scores were significantly improved from baseline at every follow-up visit (p < 0.001) and mean PASI decreased from 15.3 ± 6.3 at baseline to 0.5 ± 1.0 at week 84. Secukinumab had comparable effectiveness in biologic naïve and non-naïve patients. Conclusions: This study confirmed the effectiveness and safety of secukinumab in real-world patients with psoriasis.
Background: Long term data on the real-life use of secukinumab are scant. The aim of this study was to investigate the real-life effectiveness, safety and treatment persistence of secukinumab in patients with moderate-to-severe psoriasis. Research design and methods: This 84-week, multicenter (n = 7) retrospective study analyzed data from patients who initiated and received at least 6 months of secukinumab treatment between June 2016 and June 2018 in the Campania region of Italy. Patient demographic and treatment characteristics, duration of treatment and reasons for discontinuation as well as Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI) scores were assessed. Results: 324 patients (63% male, mean age 50.2 years) were enrolled and received a mean 11.7 months of secukinumab treatment. Overall, 9.5% discontinued secukinumab, including 5.2% who discontinued due to secondary inefficacy and 1.8% due to adverse events. PASI, BSA and DLQI scores were significantly improved from baseline at every follow-up visit (p < 0.001) and mean PASI decreased from 15.3 ± 6.3 at baseline to 0.5 ± 1.0 at week 84. Secukinumab had comparable effectiveness in biologic naïve and non-naïve patients. Conclusions: This study confirmed the effectiveness and safety of secukinumab in real-world patients with psoriasis.
Entities:
Keywords:
Anti-IL-17; PASI; biologic drugs; psoriasis; real life; secukinumab
Authors: Bruce Strober; Dhaval Patil; Robert R McLean; Melissa Moore-Clingenpeel; Ning Guo; Eugenia Levi; Mark Lebwohl Journal: Dermatol Ther (Heidelb) Date: 2022-05-13